STERIS Q1 revenue rises 8% to $1.3 billion; EPS up, fiscal 2025 outlook reiterated
STERIS reported fiscal 2025 first-quarter results for the period ended June 30, 2024. Revenue from continuing operations rose 8% to $1.3 billion, and reported diluted EPS from continuing operations increased to $1.41 from $1.31, while adjusted EPS rose to $2.03 from $1.84. The company reiterated its fiscal 2025 outlook, including adjusted EPS guidance of $9.05 to $9.25, but free cash flow fell to $195.7 million from $214.5 million.
Key points
- Revenue from continuing operations increased 8% to $1.3 billion from $1.2 billion a year earlier; constant currency organic revenue grew 6%.
- Reported diluted EPS from continuing operations was $1.41 versus $1.31; adjusted diluted EPS was $2.03 versus $1.84.
- Fiscal 2025 adjusted EPS from continuing operations is expected at $9.05 to $9.25, compared with $8.20 in fiscal 2024.
- Free cash flow was $195.7 million versus $214.5 million, which management attributed primarily to the timing of capital spending.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.